Edoxaban Tosylate Patent Expiration

Edoxaban Tosylate was first introduced by Daiichi Sankyo Inc in its drug Savaysa on Jan 8, 2015.


Edoxaban Tosylate Patents

Given below is the list of patents protecting Edoxaban Tosylate, along with the drug name that holds that patent and the company name owning that drug.

Drug Used in Drug Patent Number Drug Patent Title Drug Patent Expiry Drug Owner
Savaysa US9149532 Pharmaceutical composition Mar 28, 2028 Daiichi Sankyo Inc
Savaysa US7365205 Diamine derivatives Apr 18, 2027 Daiichi Sankyo Inc



A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Edoxaban Tosylate's patents.

Given below is the list recent legal activities going on the following patents of Edoxaban Tosylate.

Activity Date Patent Number
Patent litigations
Payment of Maintenance Fee, 8th Year, Large Entity 22 Mar, 2023 US9149532
Change in Power of Attorney (May Include Associate POA) 19 Mar, 2021 US7365205
Email Notification 19 Mar, 2021 US7365205
Patent Term Extension Certificate 16 Feb, 2021 US7365205
Change in Power of Attorney (May Include Associate POA) 03 Feb, 2021 US9149532
Email Notification 03 Feb, 2021 US9149532
Correspondence Address Change 01 Feb, 2021 US9149532
Correspondence Address Change 05 Jan, 2021 US7365205
Payment of Maintenance Fee, 12th Year, Large Entity 17 Oct, 2019 US7365205
Notice of Final Determination -Eligible 19 Sep, 2019 US7365205


Edoxaban Tosylate's Family Patents

Family Patents

Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List